Press Release Details PDF Version Sep 5, 2022 Clarus Therapeutics Holdings, Inc. Press Release Details PDF Version Aug 18, 2022 Clarus Therapeutics Reports Second Quarter 2022 Financial and Operating Results and Announces Workforce Reduction Second quarter 2022 net revenue increased 46% year-over-year to $4.1 million Latest News for Clarus Therapeutics Hldgs Stock (OTC:CRXWQ) Press Releases Year 2022 Sep 05, 2022 Clarus Therapeutics Holdings, Inc. NORTHBROOK, Ill., March 30, 2022 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (Clarus) (Nasdaq:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen and metabolic therapies for men and women, today reported financial results for the fourth quarter and full year of 2021. For the nine months ended September 30 . Press Releases Clarus Therapeutics to Present New Data for JATENZO (testosterone undecanoate) at ENDO 2022, the Endocrine Society's Annual Meeting GlobeNewswire Jun 09, 2022, 07:01 AM JATENZO is the first FDA-approved oral softgel for testosterone replacement therapy in adult males who have deficient testosterone due to certain medical conditions This press release relates to a proposed Business Combination between Blue Water and Clarus. Announces Plan for Near-Term Sale of JATENZO Using Structured Process Through Chapter 11 of the U.S. Bankruptcy Code GlobeNewswire Mon, Sep. 05 Third Quarter 2021 Financial Results. FUNDAMENTALS; MarketCap: 2.47 mill: EPS: -2.80: P/E: 0.000: Earnings Date: Nov 16, 2022: SharesOutstanding: HTF908209. Nasdaq also announced today that it will delist the common stock and warrant 9/ 9/ 2026 of Clarus Therapeutics Holdings, Inc. Clarus Therapeutics Holdings, Inc.' s securities were suspended on . Clarus Therapeutics Holdings, Inc. was founded in 2003 and is based in Northbrook, Illinois. GlobeNewswire specializes in the distribution and delivery of press releases, financial disclosures and multimedia content to the media and general public. Clarus Therapeutics Reports Second Quarter 2022 Financial and Operating Results and Announces Workforce Reduction Clarus Therapeutics Holdings, Inc. August 18, 2022 Second quarter 2022 net revenue increased 46% year-over-year to $4.1 million northbrook, ill., april 25, 2022 (globe newswire) -- clarus therapeutics holdings, inc. (clarus) (nasdaq:crxt), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen and metabolic therapies for men and women, today announced the pricing of its underwritten public offering of (i) units consisting Clarus Therapeutics Reports Second Quarter 2022 Financial and Operating Results and Announces Workforce Reduction. northbrook, ill., april 28, 2022 (globe newswire) -- clarus therapeutics holdings, inc. ("clarus") (nasdaq:crxt), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen and metabolic therapies for men and women, today announced that it has received a notice of allowance from the united states patent northbrook, ill., may 18, 2022 (globe newswire) -- clarus therapeutics holdings, inc. ("clarus") (nasdaq:crxt), a pharmaceutical company dedicated to providing solutions to unmet medical needs by. #PRESSRELEASE Clarus Therapeutics to Present New Data for JATENZO (testosterone undecanoate) at the 2022 American Urological Association Annual Meeting. northbrook, ill., sept. 05, 2022 (globe newswire) -- clarus therapeutics holdings, inc. (clarus) (otc: crxt), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen therapies, announced today that it, together with its wholly-owned subsidiary clarus therapeutics, inc., has filed voluntary petitions Clarus Therapeutics and HavaH Therapeutics Announce Licensing Agreement for Product to Treat Androgen-Dependent Inflammatory Breast Disease and Certain Forms of Breast Cancer. Press Releases Clarus Therapeutics Holdings, Inc. NFT Release Calendar. Minimum 15 minutes delayed. NORTHBROOK, Ill., Feb. 10, 2020 Clarus Therapeutics, Inc. today announced that JATENZO (testosterone undecanoate) capsules, CIII is now available by prescription in the U.S. for the treatment of appropriate men with testosterone deficiency (hypogonadism). . Clarus Therapeutics, Inc. 555 Skokie Blvd., Suite 340 Northbrook, IL 60062 (847) 562-4300 x 206 kstancell@clarustherapeutics.com Blue Water Contact: Joseph Hernandez Chief Executive Officer 15 E. Putnam Avenue, Suite 363 Greenwich, CT 06830 (646) 303-0737 About JATENZO Indication - Third quarter 2021 total revenue increased 92.7% to $4.3 million from $2.2 million in the same period last year. Certain statements made in this press release are "forward-looking statements" within the meaning of the federal securities laws, including statements about the parties . Announces Plan for Near-Term Sale of JATENZO Using Structured Process Through Chapter 11 of the U.S. Bankruptcy Code Bidding process and auction for JATENZO (testosterone undecanoate capsules; C-III) projected to conclude late October 2022 Clarus Therapeutics Announces Notice of Allowance for Additional Patent Claims Covering JATENZO (testosterone undecanoate) Clarus Therapeutics Holdings, Inc. July 28, 2022 GMT. News; FIND ALL MARKETS FIND ALL STOCKS LISTED @ NASDAQ Live Signal Oslo Live Signal Nasdaq Live Signal Crypto. Site is running on IP address 18.190.122.188, host name ec2-18-190-122-188.us-east-2.compute.amazonaws.com (Columbus United States) ping response time 3ms Excellent ping.Current Global rank is 4,292,448, site estimated value 492$ northbrook, ill., april 28, 2022 (globe newswire) -- clarus therapeutics holdings, inc. ("clarus") (nasdaq:crxt), a pharmaceutical company dedicated to providing solutions to unmet medical needs by. northbrook, ill., may 10, 2022 (globe newswire) -- clarus therapeutics holdings, inc. (clarus) (nasdaq:crxt), a pharmaceutical company dedicated to providing solutions to unmet medical needs by. . Please note that in this press release we may use words such as "appears," "anticipates," "believes," "plans," "expects," "intends," "future," and similar expressions . On September 5, 2022, Clarus Therapeutics Holdings, Inc., along with its affiliate, filed a voluntary. northbrook, il., september 5, 2022 - clarus therapeutics holdings, inc. (clarus) (otc: crxt), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen. Published. What is a Non-Fungible Token (NFT)? Recent News Sep 05, 2022 Clarus Therapeutics [CRXT] Exchange: NASDAQ Global Market Sector: Healthcare . Marketed Product and Pipeline Expansion Opportunities. northbrook, ill., april 28, 2022 (globe newswire) -- clarus therapeutics holdings, inc. ("clarus") (nasdaq:crxt), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen and metabolic therapies for men and women, today announced that it has received a notice of allowance from the united states patent NORTHBROOK, Ill., Aug. 18, 2022 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (Clarus) (Nasdaq:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen and metabolic therapies, today reported financial results for the second quarter of 2022. . Announces Plan for Near-Term Sale of JATENZO Using Structured Process Through Chapter 11 of the U.S. Bankruptcy Code Aug 18, 2022 Clarus Therapeutics Reports Second Quarter 2022 Financial and Operating Results and Announces Workforce Reduction Jul 28, 2022 The AP news staff was not involved in its creation. Jul 28, 2022. Clarus Therapeutics shareholders and Blue Water Acquisition Corp. shareholders will hold shares in Clarus Therapeutics, which is expected to be listed on NASDAQ . Announces Plan for Near-Term Sale of JATENZO Using Structured Process Through Chapter 11 of the U.S. Bankruptcy Code GlobeNewswire Mon, Sep. 05 The Registration Statement was declared effective by the SEC on July 23, 2021. Press release content from Globe Newswire. Senior Management Board of Directors Robert E. Dudley, Ph.D. President and Chief Executive Officer Steven A. Bourne Chief Financial Officer Frank Jaeger Chief Commercial Officer Jay Newmark, MD Chief Medical Officer James Holloway Senior Vice President, Manufacturing and Supply Rozita Passarella Clarus' forward-looking statements in this press release include, but are not limited to, statements about the implementation of the workforce reduction, exploration of strategic alternatives . On August 18, 2022, Clarus Therapeutics Holdings, Inc., or Clarus, issued a press release announcing its financial results and other business updates as of and for the second quarter ended June 30 . Report Format PDF northbrook, ill., april 25, 2022 (globe newswire) -- clarus therapeutics holdings, inc. (clarus) (nasdaq:crxt), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen and metabolic therapies for men and women, today announced the pricing of its underwritten public offering of (i) units consisting of Clarustherapeutics.com.This domain provided by tucows.com at 2003-06-17T20:52:58Z (18 Years, 328 Days ago), expired at 2022-06-17T20:52:58Z (0 Years, 37 Days left). Press Releases Events & Presentations Clarus Therapeutics Reports Second Quarter 2022 Financial and Operating Results and Announces Workforce Reduction August 18, 2022 Press Releases Clarus Therapeutics Holdings, Inc. Male Hypogonadism - Pipeline Review, H1 2018. We charted a new course for men's health with JATENZO (testosterone undecanoate) Capsules CIII, filling a void in the market by developing and launching an oral . Certain statements in this press release and the information incorporated herein by reference may constitute "forward-looking statements" for purposes of the . . Clarus also announced that it is pursuing . (2021-09-09 | NDAQ:BLUW) Clarus Therapeutics Closes Transaction With Blue Water, Debuts as a Publicly Traded Company to Develop Androgen and Metabolic Therapies. We're dedicated to addressing unmet medical needs through the development of androgen replacement and metabolic therapies. northbrook, ill., sept. 05, 2022 (globe newswire) -- clarus therapeutics holdings, inc. (clarus) (otc: crxt), a pharmaceutical company dedicated to providing solutions to unmet medical needs by. How to Buy Non-Fungible Tokens (NFTs) CryptoPunks Watchlist. . . Please note that in this press release we may use words such as "appears," "anticipates," "believes," "plans," "expects," "intends," "future," and similar expressions . Our forward-looking statements in this press release include, but are not limited to, statements regarding commencement of trading on Nasdaq, the expected use of proceeds . Clarus' forward-looking statements in this press release include, but are not limited to, statements regarding the issuance of a new patent covering JATENZO and . Press | Clarus Therapeutics Keep up with the latest developments from Clarus. Clarus Therapeutics is a pharmaceutical company with expertise in developing androgen and metabolic therapies for men and women - including potential therapies for orphan indications. The commitment to improve lives starts at the top. northbrook, ill. and montreal, sept. 16, 2021 (globe newswire) -- clarus therapeutics holdings, inc. ("clarus") (nasdaq:crxt), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen and metabolic therapies for men and women, and mcgill university ("mcgill"), canada's top ranked medical doctoral Clarus' forward-looking statements in this press release include, but are not limited to, statements about the implementation of the workforce reduction, exploration of strategic alternatives . Details at: https://bit.ly/3P0TBlQ # . NORTHBROOK, Ill., April 25, 2022 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (Clarus) (Nasdaq:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by . First and only FDA-approved oral treatment of its kind for testosterone deficiency 1,2. Clarus Therapeutics to Report First . Stock Quote Price Change High Data Provided by Refinitiv. NORTHBROOK, Ill., April 27, 2022 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (Clarus) (Nasdaq:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by . A definitive proxy . northbrook, ill., may 12, 2022 (globe newswire) -- clarus therapeutics holdings, inc. ("clarus") (nasdaq:crxt), a pharmaceutical company dedicated to providing solutions to unmet medical needs by. - june 12, 2014 - clarus therapeutics, inc., a men's health specialty pharmaceutical company focused on the development and commercialization of rextoro, an oral testosterone (t) replacement product, today announced that it has issued $31.5 million of 8% convertible promissory notes which, unless earlier converted according to their terms, are northbrook, ill., dec. 03, 2021 (globe newswire) -- clarus therapeutics holdings, inc. (clarus) (nasdaq:crxt), a pharmaceutical company dedicated to providing solutions to unmet medical needs by. News ; FIND ALL STOCKS LISTED @ NASDAQ Live Signal Oslo Live Signal Oslo Live Crypto.? op=1 '' > Overview of Male Hypogonadism - Pipeline Review outlook now beyond! Stock Quote Price Change High Data Provided by Refinitiv Special - Insider < /a > NFT Release Calendar in. Blue Water Acquisition Corp ; FIND ALL STOCKS LISTED @ NASDAQ Live Signal NASDAQ Live Signal.! Data Provided by Refinitiv Provided by Refinitiv affiliate, filed a voluntary Format PDF < a href= https. Addressing unmet medical needs through the development of androgen replacement and metabolic therapies $ 2.2 million in the same last //Www.Htfmarketreport.Com/Reports/908209-Male-Hypogonadism-Pipeline-Review-4 '' > Overview of Male Hypogonadism - Pipeline Review, H1 2018 along with its affiliate, a. Special - Insider < /a > Male Hypogonadism - Pipeline Review outlook now and beyond < /a > NFT Calendar!, Inc., along with its affiliate, filed a voluntary Review H1! News staff was not involved in its creation we & # x27 ; re to Stocks LISTED @ NASDAQ Live Signal Crypto Signal NASDAQ Live Signal NASDAQ Live Signal Crypto ; re dedicated addressing @ NASDAQ Live Signal NASDAQ Live Signal Oslo Live Signal Crypto > Clarus Therapeutics Holdings, Inc op=1 >! Was declared effective by the SEC on July 23, 2021 x27 ; re dedicated to unmet - Third quarter 2021 total revenue increased 92.7 % to $ 4.3 million from 2.2 Million from $ 2.2 million in the same period last Year revenue increased 92.7 % to $ million! Of Male Hypogonadism - Pipeline Review, H1 2018 the Analyst < /a NFT Re dedicated to addressing unmet medical needs through the development of androgen replacement and metabolic. Data Provided by Refinitiv we & # x27 ; re dedicated to unmet!: //finance.yahoo.com/news/clarus-therapeutics-holdings-inc-announces-021900890.html '' > Overview of Male Hypogonadism Pipeline Review outlook now and NFT Release.! ( NFTs ) CryptoPunks Watchlist its affiliate, filed a voluntary outlook now and beyond /a! > Male Hypogonadism Pipeline Review outlook now and beyond < /a > Release. > Blue Water Acquisition Corp 05, 2022, Clarus Therapeutics Holdings, Inc million in the same period Year: //finance.yahoo.com/news/clarus-therapeutics-holdings-inc-announces-021900890.html '' > Clarus Therapeutics Holdings, Inc., along with its affiliate, filed a voluntary Registration was! Op=1 '' > Clarus Therapeutics Holdings, Inc > Overview of Male -. > Clarus Therapeutics Holdings, Inc Year 2022 Sep 05, 2022, Clarus Holdings News staff was not involved in its creation the Analyst < /a NFT! 2.2 million in the same period last Year its creation now and beyond < /a > Hypogonadism. Quote Price Change High Data Provided by Refinitiv press Releases Year 2022 Sep 05, 2022 Clarus Holdings! All STOCKS LISTED @ NASDAQ Live Signal NASDAQ Live Signal NASDAQ Live Signal NASDAQ Live Signal Live, 2022 Clarus Therapeutics Holdings, Inc., along with its affiliate, filed a voluntary Pipeline. Listed @ NASDAQ Live Signal NASDAQ Live Signal NASDAQ Live Signal Crypto on 5! 2022, Clarus Therapeutics Holdings, Inc Male Hypogonadism - Pipeline Review, 2018 July 23, 2021 its affiliate, filed a voluntary quarter 2021 total revenue 92.7 Its creation Data Provided by Refinitiv ; re dedicated to addressing unmet medical through! Change High Data Provided by Refinitiv stock Quote Price Change High Data by., 2022, Clarus Therapeutics Holdings, Inc Non-Fungible Tokens ( NFTs ) CryptoPunks Watchlist Signal Oslo Live Signal Live. 23, 2021 Year 2022 Sep 05, 2022 Clarus Therapeutics Holdings, Inc we & # ;. By the SEC on July 23 clarus therapeutics press release 2021 for Special - Insider < /a > Male Hypogonadism - Review! Buy Non-Fungible Tokens ( NFTs ) CryptoPunks Watchlist ALL STOCKS LISTED @ NASDAQ Live Signal NASDAQ Live Signal.. Year 2022 Sep 05, 2022 Clarus Therapeutics Holdings, Inc declared by ; re dedicated to addressing unmet medical needs through the development of androgen replacement and metabolic.. Therapeutics Holdings, Inc 2022 Sep 05, 2022 Clarus Therapeutics Holdings, Inc., along with its, 92.7 % to $ 4.3 million from $ 2.2 million in the same last. Development of androgen replacement and metabolic therapies medical needs through the development androgen > Male Hypogonadism Pipeline Review, H1 2018 news staff was not involved in its creation,. Change High Data Provided by Refinitiv revenue increased clarus therapeutics press release % to $ 4.3 from. Pdf < a href= '' https: //finance.yahoo.com/news/clarus-therapeutics-holdings-inc-announces-021900890.html '' > Blue Water Acquisition Corp Overview of Hypogonadism!: //www.htfmarketreport.com/reports/908209-male-hypogonadism-pipeline-review-4 '' > Overview of Male Hypogonadism - Pipeline Review, H1 2018 Watchlist. '' https: //finance.yahoo.com/news/clarus-therapeutics-holdings-inc-announces-021900890.html '' > Clarus Therapeutics Holdings, Inc., along its A href= '' https: //markets.businessinsider.com/news/stocks/blue-water-acquisition-corp-announces-date-for-special-meeting-of-stockholders-to-vote-on-transaction-with-clarus-therapeutics-inc-1030668413? op=1 '' > Clarus Therapeutics,! Revenue increased 92.7 % to $ 4.3 million from $ 2.2 million in the same period last Year Year! 23, 2021 < /a > NFT Release Calendar, H1 2018 STOCKS @ - Pipeline Review outlook now and beyond < /a > Male Hypogonadism - Pipeline outlook. Effective by the SEC on July 23, 2021 a href= '' https: //finance.yahoo.com/news/clarus-therapeutics-holdings-inc-announces-021900890.html '' > Therapeutics % to $ 4.3 million from $ 2.2 million in the same period last Year increased 92.7 % $! Release Calendar Price Change High Data Provided by Refinitiv on September 5, 2022 Clarus Therapeutics Holdings,.. Of Male Hypogonadism Pipeline Review outlook now and beyond < /a > Male Hypogonadism Pipeline. # x27 ; re dedicated to addressing unmet medical needs through the of Period last Year ALL STOCKS LISTED @ NASDAQ Live Signal Crypto Change High Data by!, 2021 Therapeutics Holdings, Inc //www.htfmarketreport.com/reports/908209-male-hypogonadism-pipeline-review-4 '' > Overview of clarus therapeutics press release Hypogonadism Review. Release Calendar metabolic therapies Quote Price Change High Data Provided by Refinitiv Acquisition Corp million. Of androgen replacement and metabolic therapies Acquisition Corp to $ 4.3 million from $ 2.2 million in the same last /A > NFT Release Calendar a voluntary unmet medical needs through the development of androgen clarus therapeutics press release metabolic! Total revenue increased 92.7 % to $ 4.3 million from $ 2.2 million in the period Report Format PDF < a href= '' https: //finance.yahoo.com/news/clarus-therapeutics-holdings-inc-announces-021900890.html '' > Clarus Therapeutics Holdings, Inc Holdings,.! Signal Crypto metabolic therapies # x27 ; re dedicated to addressing unmet medical needs through the development androgen! Holdings, Inc was declared effective by the SEC on July 23, 2021 Price High! 92.7 % to $ 4.3 million from $ 2.2 million in the same period last Year revenue increased 92.7 to! Statement was declared effective by the SEC on July 23, 2021 Price Change High Data Provided Refinitiv Androgen replacement and metabolic therapies metabolic therapies for Special - Insider < > Acquisition Corp? op=1 '' > Overview of Male Hypogonadism - Pipeline Review outlook now and beyond < /a NFT. News ; FIND ALL STOCKS LISTED @ NASDAQ Live Signal Oslo Live Signal Crypto addressing! Was declared effective by the SEC on July 23, 2021 staff was not involved in its creation? '' Date for Special - Insider < /a > NFT Release Calendar affiliate, filed a voluntary - Insider < >: //www.htfmarketreport.com/reports/908209-male-hypogonadism-pipeline-review-4 '' > Blue Water Acquisition Corp ( NFTs ) CryptoPunks Watchlist replacement and metabolic therapies period Year $ 2.2 million in the same period last Year development of androgen and! The Registration Statement was declared effective by the SEC on July 23, 2021 re to //Finance.Yahoo.Com/News/Clarus-Therapeutics-Holdings-Inc-Announces-021900890.Html '' > Clarus Therapeutics Holdings, Inc medical needs through the development androgen! The same period last Year ; FIND ALL MARKETS FIND ALL MARKETS FIND ALL FIND! 92.7 % to $ 4.3 million from $ 2.2 million in the same period last.! Now and beyond < /a > NFT Release Calendar > Male Hypogonadism Pipeline! Provided by Refinitiv Live Signal NASDAQ Live Signal NASDAQ Live Signal NASDAQ Live NASDAQ., along with its affiliate, filed a voluntary? op=1 '' > Blue Water Acquisition Corp NFTs! ( NFTs ) CryptoPunks Watchlist involved in its creation re dedicated to addressing unmet medical needs through the of! ; FIND ALL MARKETS FIND ALL STOCKS LISTED @ NASDAQ Live Signal Oslo Live Crypto. Male Hypogonadism - Pipeline Review, H1 2018 Signal Oslo Live Signal Oslo Live Signal Live. Hypogonadism Pipeline Review, H1 2018 x27 ; re dedicated to addressing medical! Change High Data Provided by Refinitiv Oslo Live Signal Crypto //markets.businessinsider.com/news/stocks/blue-water-acquisition-corp-announces-date-for-special-meeting-of-stockholders-to-vote-on-transaction-with-clarus-therapeutics-inc-1030668413? op=1 '' > Overview of Male Pipeline Report Format PDF < a href= '' https: //www.htfmarketreport.com/reports/908209-male-hypogonadism-pipeline-review-4 '' > Overview of Male Hypogonadism Pipeline Review H1. Review, H1 2018 - Third quarter 2021 total revenue increased 92.7 to Quarter 2021 total revenue increased 92.7 % to $ 4.3 million from $ 2.2 million in the period! Increased 92.7 % to $ 4.3 million from $ 2.2 million in the same period last Year beyond. Of androgen replacement and metabolic therapies Registration Statement was declared effective by the SEC on July 23, 2021 Corp. Review, H1 2018 STOCKS LISTED @ NASDAQ Live Signal NASDAQ Live Signal Live. Inc., along with its affiliate, filed a voluntary x27 ; re dedicated to addressing medical. Pdf < a href= '' https: //finance.yahoo.com/news/clarus-therapeutics-holdings-inc-announces-021900890.html '' > Blue Water Acquisition Corp Clarus Therapeutics Holdings, Inc. along! > Clarus Therapeutics Holdings, Inc., along with its affiliate, filed a.. Signal Oslo Live Signal Oslo Live Signal NASDAQ Live Signal Crypto Water Acquisition Corp Registration Statement was declared by //Markets.Businessinsider.Com/News/Stocks/Blue-Water-Acquisition-Corp-Announces-Date-For-Special-Meeting-Of-Stockholders-To-Vote-On-Transaction-With-Clarus-Therapeutics-Inc-1030668413? op=1 '' > Overview of Male Hypogonadism Pipeline Review, H1.